Optic IconOptic Logo
|
SearchCollectionsBenchmarks

rHuPH20

3 clinical trials

2 abstracts

3 indications

Indication
HIV
Indication
Melanoma
Indication
Multiple Sclerosis
Clinical trial
VRC 609: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) to Healthy Adults
Status: Completed, Estimated PCD: 2022-08-29
Abstract
A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma.
Org: Alaska Oncology and Hematology, LLC., Bristol Myers Squibb Research,
Clinical trial
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis
Status: Active (not recruiting), Estimated PCD: 2025-06-20
Abstract
Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.
Org: Drug Development Unit at Royal Marsden Hospital/Institute of Cancer Research, Sutton, United Kingdom, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,